Tropé C, Aspegren K, Kullander S, Astedt B
Acta Obstet Gynecol Scand. 1979;58(6):543-6. doi: 10.3109/00016347909154616.
Cell suspensions from nine human ovarian primary cancers, their metastases and ascitic cells were treated in vitro with amethopterin and melphalan. Effects were measured by incorporation of H3-TdR or H3-UdR into the cells. There was significant heterogeneity of cytostatic effects on cells from the three sources in a given patient. Ascitic cells did nt represent a "mean" of the cancer cell clones. The implications of these findings should be considered if cytostatic in vitro prediction tests are used to guide cytostatic treatment of patients.
来自九例人类卵巢原发性癌、其转移灶及腹水细胞的细胞悬液,在体外分别用氨甲蝶呤和马法兰进行处理。通过检测H3-胸腺嘧啶核苷(H3-TdR)或H3-尿嘧啶核苷(H3-UdR)掺入细胞的情况来测定效果。在给定患者中,对来自这三种来源的细胞的细胞抑制作用存在显著异质性。腹水细胞并不代表癌细胞克隆的“平均值”。如果使用体外细胞抑制预测试验来指导患者的细胞抑制治疗,就应该考虑这些发现的意义。